Business
AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update
Initiated a global Phase 2b trial to treat atopic dermatitis with ANB032, a BTLA agonistHosting a virtual BTLA Agonist (ANB032) R&D Event on May 25,
About this update from Anaptysbio, Inc.
[{"type":"text","content":"Initiated a global Phase 2b trial to treat atopic dermatitis with ANB032, a BTLA agonistHosting a virtual BTLA Agonist (ANB032) R&D Event on May 25, 2023Announced International Societies for Investigative Dermatology (ISID) Annual Meeting poster presentation for ANB032, a BTLA agonist, Phase 1 dataInitiating a global Phase 2b trial to treat rheumatoid arthritis in Q3 2023 and a second Phase 2 trial, in an indication to be announced, by year-end 2023 with rosnilimab, a PD-1 agonistReiterating cash runway through year-end 2026 with expected year-end 2023 cash and investments of $370 – $385 million SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the first quarter ended March 31, 2023 and provided pipeline updates. “We’re excited about our progress as we continue to develop best-in-class antibodies across a number of high-value immune cell modulatory targets. We have initiated our global Phase 2b trial in moderate-to-severe atopic dermatitis (AD) for ANB032, our BTLA agonist, and will host a virtual R&D event on May 25th to highlight the biologic and mechanistic rationale for developing a BTLA agonist in AD,\" said Daniel Faga, interim president and chief executive officer of AnaptysBio. \"We believe our checkpoint agonists, rosnilimab and ANB032, as well as our CD122 antagonist, ANB033, have the potential to treat a broad range of autoimmune and inflammatory disorders by directly acting on immune cells that mediate disease pathology, and we remain well capitalized to execute on our broad development plan.\" Updates on Wholly Owned Immune Cell Modulator Pipeline Rosnilimab (PD-1 agonist antibody) Anticipate initiation in Q3 2023 of a global Phase 2b trial in moderate-to-severe rheumatoid arthritis (RA) Multi-hundred patient placebo-controlled trial assessing three dose levels of subcutaneously administered rosnilimab for up to 6 months on well-established endpoints including ACR20/50/70 and DAS28Top-line interim data anticipated by mid-year 2025 Plan to initiate second global Phase 2 trial, in an indication to be announced, by year-end 2023 ANB032 (BTLA agonist antibody) Initiated a global Phase 2b trial in moderate-to-severe AD 160 patient placebo-controlled trial assessi...